Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.

Experimental hematology - 1 Mar 2013

Amaru Calzada Ariel, Pedrini Olga, Finazzi Guido, Leoni Flavio, Mascagni Paolo, Introna Martino, Rambaldi Alessandro, Golay Josée

Abstract excerpt

We investigated whether clinically achievable concentrations of the histone deacetylase (HDAC) inhibitors givinostat and hydroxyurea induce synergistic cytotoxicity in Jak2(V617F) cells in vitro and through which possible mechanism. Givinostat and hydroxyurea at low doses potentiated the pro-apoptotic effects of each other in the Jak2(V617F) HEL and UKE1 cell lines. Givinostat induced 6.8%-20.8% and hydroxyurea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Caspase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Drug Synergism

Share to Hydroxyurea

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Source

Identifiers

PMID: 23111067
DOI: 10.1016/j.exphem.2012.10.013

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.PMID 23111067Read ↗

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.Semantic proximity Read ↗

Givinostat: an emerging treatment for polycythemia vera.Semantic proximity Read ↗

Synergistic Antileukemic Effects of Hydroxyurea and SRJ23 in T-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.Semantic proximity Read ↗

The Cell Killing Mechanisms of HydroxyureaSemantic proximity Read ↗

Pharmacological evaluation of drug therapies in Aicardi-Goutières syndrome: insights from patient-derived neural stem cellsSemantic proximity Read ↗

Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.Semantic proximity Read ↗

Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir.Semantic proximity Read ↗

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cellsSemantic proximity Read ↗

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.Semantic proximity Read ↗

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemiaSemantic proximity Read ↗

Combination of artesunate and ruxolitinib inhibits T-lymphoblastic leukemia/lymphoma proliferation via the Janus kinase/signal transducer and activator of transcription pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.